Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Michael M Boyiadzis; Madhav V Dhodapkar; Renier J Brentjens; James N Kochenderfer; Sattva S Neelapu; Marcela V Maus; David L Porter; David G Maloney; Stephan A Grupp; Crystal L Mackall; Carl H June; Michael R Bishop

doi:10.1186/s40425-018-0460-5

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5.

Authors

Affiliations

¹ University of Pittsburgh, Pittsburgh, PA, USA.
² Winship Cancer Institute, Emory University, Atlanta, GA, USA.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD, USA.
⁵ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
⁷ Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
⁸ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁹ Division of Oncology, Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹⁰ Cancer Immunology and Immunotherapy Program, Stanford University, Stanford, CA, USA.
¹¹ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA. mbishop@medicine.bsd.uchicago.edu.
¹² The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA. mbishop@medicine.bsd.uchicago.edu.

Abstract

Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.

Keywords: Axicabtagene ciloleucel; Chimeric antigen receptor; Leukemia; Lymphoma; Tisagenlecleucel.

Publication types

Review

MeSH terms

Animals
Antigens, Neoplasm / immunology
Clinical Trials as Topic
Genetic Engineering
Hematologic Neoplasms / diagnosis
Hematologic Neoplasms / immunology*
Hematologic Neoplasms / therapy*
Humans
Immunotherapy, Adoptive* / adverse effects
Immunotherapy, Adoptive* / methods
Receptors, Antigen, T-Cell / genetics
Receptors, Antigen, T-Cell / metabolism*
Receptors, Chimeric Antigen / genetics
Receptors, Chimeric Antigen / metabolism*
T-Lymphocytes / immunology*
T-Lymphocytes / metabolism*
Treatment Outcome

Substances

Antigens, Neoplasm
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding